On December 7, 2012, PROLOR Biotech, Inc., a Nevada corporation (the "Company"), issued a press release announcing that it will present preclinical data on its long-acting clotting Factor VIIa (Factor VIIa-CTP) at the 54th Annual Meeting of the American Society of Hematology on December 8, 2012 (the "ASH Meeting"). A copy of the press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.

At the ASH Meeting, the Company will present a poster presentation, a copy which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended.

(d) Exhibits.

                 Exhibit
                 Number                 Description
                  99.1     Press Release, dated December 7, 2012
                  99.2     Poster Presentation